Gene Delivery System Market

Gene Delivery System Market (Delivery System: Viral Gene Delivery, Non-viral Gene Delivery, and Combined Hybrid Delivery) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Gene Delivery System Market Outlook 2031

  • The global industry was valued at US$ 5.4 Bn in 2022
  • It is estimated to grow at a CAGR of 7.2% from 2023 to 2031 and reach US$ 10.0 Bn by the end of 2031

Analyst Viewpoint

The global gene delivery system industry size is driven by rise in incidence of genetic disorders and advancements in gene therapy research. Stakeholders in the market are developing safer and more efficient viral vectors for gene delivery. Targeted and low-dose frequency drug delivery systems are also gaining traction in the gene delivery system market statistics.

Increase in investment in biotechnology and pharmaceutical research is likely to offer lucrative opportunities to vendors in the global gene delivery system industry. However, high cost of gene therapy and surge in drug recalls due to stringent regulations in developed countries are estimated to limit the gene delivery system market growth in the near future.

Gene Delivery System Market

Market Introduction

Gene delivery is a procedure that introduces foreign DNA into host cells. Gene delivery systems are used to deliver therapeutic drugs targeting a specific area. Gene therapy administers an appropriate material to replace a defective or missing gene.

It is primarily employed in the treatment of inherited genetic disorders. Gene therapy is also used in the treatment of other diseases such as autosomal or X-linked recessive single-gene disorders, sickle cell anemia, phenylketonuria, hemophilia, and Duchenne muscular dystrophy.

Viral gene delivery, non-viral gene delivery, and combined hybrid are various types of gene delivery systems. Viral gene delivery systems include viral gene delivery, adenovirus vector, lentivirus vector, retrovirus vector, adeno-associated virus vector, sendai virus vector, and herpes simplex virus vector.

Natural organic compounds, physical methods, and chemical methods are major types of non-viral gene delivery systems. Viral vectors are one of the most successful genetic material transport systems. These vectors include retrovirus, adenovirus (types 2 and 5), adeno-associated virus, herpes virus, pox virus, human foamy virus (HFV), and lentivirus.

Rise in Incidence of Genetic Disorders Fueling Gene Delivery System Market Development

Gene delivery systems are essentially necessary for the gene therapy of human genetic diseases. Genetic diseases seriously threaten human health. siRNA, shRNA, antisense oligonucleotide, CRISPR/Cas9 system, plasmid DNA, miRNA, and other gene therapy drugs have shown great potential in the treatment of various diseases, including viral infections, certain cancers, and genetic disorders. Thus, high prevalence of genetic disorders is boosting the gene delivery system market demand. According to a report published by MJH Life Sciences (U.S.) in 2022, approximately 300,000 infants are born with sickle cell disease per year globally, and nearly 5% of the world's population is affected by the disease.

Advancements in Gene Therapy Research Driving Market Revenue

Development of new generations of precise vectors with sustainable effects is expected to augment the gene delivery system market progress in the near future. Limitations of existing vectors have prompted the use of modified recombinant non-replicative herpes simplex virus-1 (HSV-1) vectors. These vectors have the potential to expand future applications for gene therapy.

HSV has many features that make it a potentially attractive vehicle for gene transfer most particularly to neurons.

Recent developments in drug delivery systems are primarily focused on smart drug delivery. Safe, efficient, and specific delivery of therapeutic genes plays a major role in the development of gene therapy. Synthetic vector systems are gaining traction in this regard due to their safety, lack of immunogenicity, very low frequency of integration, and relative ease of large-scale production.

Moreover, conventional drug delivery systems offer various disadvantages such as poor bioavailability and fluctuations in plasma drug levels. Thus, targeted and low-dose frequency drug delivery systems are gaining popularity in the treatment of various diseases. This, in turn, is fueling the gene delivery system market value.

High Demand for Viral Gene Delivery Systems

According to the latest gene delivery system market trends, the viral gene delivery system segment held largest share in 2022. Increase in demand for viral gene delivery systems for the treatment of genetic and acquired diseases is driving the segment.

Lentiviral vector is one of the preferred tools for ex vivo transgene delivery for gene therapy. Lentiviruses, unlike some other viral vectors, can transduce both dividing and non-dividing cells. Thus, they are ideal vehicles to investigate combinatorial gene transfer into diverse cells.

Extensive Use of Gene Delivery Systems in Oncology

According to the latest gene delivery system market forecast, the oncology application segment is expected to account for major share from 2023 to 2031. Growth of the segment can be ascribed to the rise in the incidence of cancer across all regions. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths were projected to occur in the U.S., according to the National Center for Health Statistics.

Surge in Adoption of Injectable Gene Delivery

According to the latest gene delivery system market research, the injectable route of administration segment held largest share in 2022. The injectable route of administration is used for rapid drug absorption. Especially, drugs with low oral bioavailability are administered through the intramuscular or subcutaneous route. Oral formulations are inexpensive as compared to other dosage forms. This route of drug administration allows sustained release of formulation to reduce the frequency of the medication.

Regional Outlook

North America accounted for major gene delivery system market share in 2022. Rise in prevalence of genetic disorders and technological advancements in drug delivery systems are driving the market dynamics of the region. The prevalence of children aged 0 to 17 years with a reported genetic condition in the U.S. was approximately 0.039, roughly equating to 2.8 million children in 2016-2017, according to a 2022 study published in the journal Genetics in Medicine.

Analysis of Major Players in Gene Delivery System Market

Gene delivery system manufacturers are harnessing the power of biotechnology, chemistry, and genetic medicine to offer products that redefine the treatment of various disorders. Gene therapy is generally expensive as their development involves extensive research and development efforts. Thus, vendors are investing in innovative clinical trials to offer medicines that are accessible and affordable.

Safety is a major concern in gene therapy. There have been several product recalls in the recent past. In November 2023, Bayer voluntarily recalled a single lot of its cancer therapy Vitrakvi (larotrectinib) oral solution 20mg/mL, available in 100mL glass bottles.

Vitrakvi treats NTRK gene fusion-positive solid tumors. Patients receiving the drug may therefore already be immunocompromised. Hence, gene delivery system companies are focusing on careful product design, rigorous testing, and ongoing monitoring to enhance safety in gene therapy. They are also adopting in vivo imaging techniques for monitoring gene delivery system efficacy.

Major players operating in the market include Novartis AG, Amgen Inc., Oxford Biomedica PLC, Sibiono GeneTech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Pfizer, Inc., Bayer AG, Johnson & Johnson Services, Inc., and Human Stem Cells Institute.

The gene delivery system market report highlights these companies in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In January 2024, ProBioGen announced that the Japan Patent Office (JPO) granted the first patent for the company’s DirectedLuck technology. This advanced gene delivery system is anchored in a highly potent transposase fusion variant, facilitating epigenetic targeting alongside a meticulously designed transposon.
  • In January 2024, Novartis partnered with Voyager Therapeutics to develop gene therapies for Huntington’s disease and spinal muscular atrophy based on Voyager’s adeno-associated virus capsid discovery platform

Gene Delivery System Market Snapshot

Attribute Detail
Market Value in 2022 (Base Year) US$ 5.4 Bn
Market Forecast Value in 2031 US$ 10.0 Bn
Growth Rate (CAGR) 7.2%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis.
Competition Landscape
  • Prominent Players – Competition Dashboard and Revenue Share Analysis, 2022
  • Company Profiles (Details – Company Overview, Sales Area/Geographical Presence, Revenue, Strategy & Business Overview)
Format Electronic (PDF) + Excel
Market Segmentation
  • Delivery System
    • Viral Gene Delivery
      • Adenovirus Vector
      • Lentivirus Vector
      • Retrovirus Vector
      • Adeno-associated Virus Vector
      • Sendai Virus Vector
      • Herpes Simplex Virus Vector
      • Others
    • Non-viral Gene Delivery
      • Natural Organic Compounds
      • Physical Methods
      • Chemical Methods
    • Combined Hybrid Delivery
  • Application
    • Infectious Diseases
    • Oncology
    • Ophthalmology
    • Urology
    • Diabetes
    • CNS
    • Others
  • Route of Administration
    • Oral
    • Injectable
    • Inhalation
    • Transdermal
    • Ocular
    • Nasal
    • Topical
Regions Covered
  • North America
  • Latin America
  • Asia Pacific
  • Europe
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia & CIS
  • China
  • India
  • Japan
  • ASEAN
  • Brazil
  • Mexico
  • South Africa
Companies Profiled
  • Novartis AG
  • Amgen Inc.
  • Oxford Biomedica PLC
  • Sibiono GeneTech Co., Ltd.
  • Shanghai Sunway Biotech Co., Ltd.
  • Pfizer, Inc.
  • Bayer AG
  • Johnson & Johnson Services, Inc.
  • Human Stem Cells Institute
Customization Scope Available upon Request
Pricing Available upon Request

Frequently Asked Questions

How big was the gene delivery system market in 2022?

It was valued at US$ 5.4 Bn in 2022

How is the gene delivery system industry expected to grow during the forecast period?

It is projected to grow at a CAGR of 7.2% from 2023 to 2031

What are the key factors driving the demand for gene delivery systems?

Rise in incidence of genetic disorders and advancements in gene therapy research

Which delivery system segment held the largest share in the gene delivery system landscape in 2022?

The viral gene delivery system was the largest delivery system segment in 2022

Which region was the most lucrative in the gene delivery system business in 2022?

North America was the most lucrative region in 2022

Who are the prominent gene delivery system manufacturers?

Novartis AG, Amgen Inc., Oxford Biomedica PLC, Sibiono GeneTech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Pfizer, Inc., Bayer AG, Johnson & Johnson Services, Inc., and Human Stem Cells Institute

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gene Delivery System Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Definition

        4.1.2. Industry Evolution/Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Gene Delivery System Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Pipeline Analysis

    5.2. Key Product/Brand Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Gene Delivery System Market Analysis and Forecast, by Delivery System

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Delivery System, 2017–2031

        6.3.1. Viral Gene Delivery

            6.3.1.1. Adenovirus Vector

            6.3.1.2. Lentivirus Vector

            6.3.1.3. Retrovirus Vector

            6.3.1.4. Adeno-associated Virus Vector

            6.3.1.5. Sendai Virus Vector

            6.3.1.6. Herpes Simplex Virus Vector

            6.3.1.7. Others

        6.3.2. Non-viral Gene Delivery

            6.3.2.1. Natural Organic Compounds

            6.3.2.2. Physical Methods

            6.3.2.3. Chemical Methods

        6.3.3. Combined Hybrid Delivery

    6.4. Market Attractiveness Analysis, by Delivery System

7. Global Gene Delivery System Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Application, 2017–2031

        7.3.1. Infectious Diseases

        7.3.2. Oncology

        7.3.3. Ophthalmology

        7.3.4. Urology

        7.3.5. Diabetes

        7.3.6. CNS

        7.3.7. Others

    7.4. Market Attractiveness Analysis, by Application

8. Global Gene Delivery System Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Route of Administration, 2017–2031

        8.3.1. Oral

        8.3.2. Injectable

        8.3.3. Inhalation

        8.3.4. Transdermal

        8.3.5. Ocular

        8.3.6. Nasal

        8.3.7. Topical

    8.4. Market Attractiveness Analysis, by Application

9. Global Gene Delivery System Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region, 2017–2031

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Gene Delivery System Market Analysis and Forecast

    10.1. Introduction

    10.2. Key Findings

    10.3. Market Value Forecast, by Delivery System, 2017–2031

        10.3.1. Viral Gene Delivery

            10.3.1.1. Adenovirus Vector

            10.3.1.2. Lentivirus Vector

            10.3.1.3. Retrovirus Vector

            10.3.1.4. Adeno-associated Virus Vector

            10.3.1.5. Sendai Virus Vector

            10.3.1.6. Herpes Simplex Virus Vector

            10.3.1.7. Others

        10.3.2. Non-viral Gene Delivery

            10.3.2.1. Natural Organic Compounds

            10.3.2.2. Physical Methods

            10.3.2.3. Chemical Methods

            10.3.2.4. Acute Dialysis Products

        10.3.3. Combined Hybrid Delivery

    10.4. Market Value Forecast, by Application, 2017–2031

        10.4.1. Infectious Diseases

        10.4.2. Oncology

        10.4.3. Ophthalmology

        10.4.4. Urology

        10.4.5. Diabetes

        10.4.6. CNS

        10.4.7. Others

    10.5. Market Value Forecast, by Route of Administration, 2017–2031

        10.5.1. Oral

        10.5.2. Injectable

        10.5.3. Inhalation

        10.5.4. Transdermal

        10.5.5. Ocular

        10.5.6. Nasal

        10.5.7. Topical

    10.6. Market Value Forecast, by Country, 2017–2031

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis

        10.7.1. By Delivery System

        10.7.2. By Application

        10.7.3. By Route of Administration

        10.7.4. By Country

11. Europe Gene Delivery System Market Analysis and Forecast

    11.1. Introduction

    11.2. Key Findings

    11.3. Market Value Forecast, by Delivery System, 2017–2031

        11.3.1. Viral Gene Delivery

            11.3.1.1. Adenovirus Vector

            11.3.1.2. Lentivirus Vector

            11.3.1.3. Retrovirus Vector

            11.3.1.4. Adeno-associated Virus Vector

            11.3.1.5. Sendai Virus Vector

            11.3.1.6. Herpes Simplex Virus Vector

            11.3.1.7. Others

        11.3.2. Non-viral Gene Delivery

            11.3.2.1. Natural Organic Compounds

            11.3.2.2. Physical Methods

            11.3.2.3. Chemical Methods

            11.3.2.4. Acute Dialysis Products

        11.3.3. Combined Hybrid Delivery

    11.4. Market Value Forecast, by Application, 2017–2031

        11.4.1. Infectious Diseases

        11.4.2. Oncology

        11.4.3. Ophthalmology

        11.4.4. Urology

        11.4.5. Diabetes

        11.4.6. CNS

        11.4.7. Others

    11.5. Market Value Forecast, by Route of Administration, 2017–2031

        11.5.1. Oral

        11.5.2. Injectable

        11.5.3. Inhalation

        11.5.4. Transdermal

        11.5.5. Ocular

        11.5.6. Nasal

        11.5.7. Topical

    11.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.6.1. Germany

        11.6.2. U.K.

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Rest of Europe

    11.7. Market Attractiveness Analysis

        11.7.1. By Delivery System

        11.7.2. By Application

        11.7.3. By Route of Administration

        11.7.4. By Country/Sub-region

12. Asia Pacific Gene Delivery System Market Analysis and Forecast

    12.1. Introduction

    12.2. Key Findings

    12.3. Market Value Forecast, by Delivery System, 2017–2031

        12.3.1. Viral Gene Delivery

            12.3.1.1. Adenovirus Vector

            12.3.1.2. Lentivirus Vector

            12.3.1.3. Retrovirus Vector

            12.3.1.4. Adeno-associated Virus Vector

            12.3.1.5. Sendai Virus Vector

            12.3.1.6. Herpes Simplex Virus Vector

            12.3.1.7. Others

        12.3.2. Non-viral Gene Delivery

            12.3.2.1. Natural Organic Compounds

            12.3.2.2. Physical Methods

            12.3.2.3. Chemical Methods

            12.3.2.4. Acute Dialysis Products

        12.3.3. Combined Hybrid Delivery

    12.4. Market Value Forecast, by Application, 2017–2031

        12.4.1. Infectious Diseases

        12.4.2. Oncology

        12.4.3. Ophthalmology

        12.4.4. Urology

        12.4.5. Diabetes

        12.4.6. CNS

        12.4.7. Others

    12.5. Market Value Forecast, by Route of Administration, 2017–2031

        12.5.1. Oral

        12.5.2. Injectable

        12.5.3. Inhalation

        12.5.4. Transdermal

        12.5.5. Ocular

        12.5.6. Nasal

        12.5.7. Topical

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. China

        12.6.2. Japan

        12.6.3. India

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Market Attractiveness Analysis

        12.7.1. By Delivery System

        12.7.2. By Application

        12.7.3. By Route of Administration

        12.7.4. By Country/Sub-region

13. Latin America Gene Delivery System Market Analysis and Forecast

    13.1. Introduction

    13.2. Key Findings

    13.3. Market Value Forecast, by Delivery System, 2017–2031

        13.3.1. Viral Gene Delivery

            13.3.1.1. Adenovirus Vector

            13.3.1.2. Lentivirus Vector

            13.3.1.3. Retrovirus Vector

            13.3.1.4. Adeno-associated Virus Vector

            13.3.1.5. Sendai Virus Vector

            13.3.1.6. Herpes Simplex Virus Vector

            13.3.1.7. Others

        13.3.2. Non-viral Gene Delivery

            13.3.2.1. Natural Organic Compounds

            13.3.2.2. Physical Methods

            13.3.2.3. Chemical Methods

            13.3.2.4. Acute Dialysis Products

        13.3.3. Combined Hybrid Delivery

    13.4. Market Value Forecast, by Application, 2017–2031

        13.4.1. Infectious Diseases

        13.4.2. Oncology

        13.4.3. Ophthalmology

        13.4.4. Urology

        13.4.5. Diabetes

        13.4.6. CNS

        13.4.7. Others

    13.5. Market Value Forecast, by Route of Administration, 2017–2031

        13.5.1. Oral

        13.5.2. Injectable

        13.5.3. Inhalation

        13.5.4. Transdermal

        13.5.5. Ocular

        13.5.6. Nasal

        13.5.7. Topical

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis

        13.7.1. By Delivery System

        13.7.2. By Application

        13.7.3. By Route of Administration

        13.7.4. By Country/Sub-region

14. Middle East & Africa Gene Delivery System Market Analysis and Forecast

    14.1. Introduction

    14.2. Key Findings

    14.3. Market Value Forecast, by Delivery System, 2017–2031

        14.3.1. Viral Gene Delivery

            14.3.1.1. Adenovirus Vector

            14.3.1.2. Lentivirus Vector

            14.3.1.3. Retrovirus Vector

            14.3.1.4. Adeno-associated Virus Vector

            14.3.1.5. Sendai Virus Vector

            14.3.1.6. Herpes Simplex Virus Vector

            14.3.1.7. Others

        14.3.2. Non-viral Gene Delivery

            14.3.2.1. Natural Organic Compounds

            14.3.2.2. Physical Methods

            14.3.2.3. Chemical Methods

            14.3.2.4. Acute Dialysis Products

        14.3.3. Combined Hybrid Delivery

    14.4. Market Value Forecast, by Application, 2017–2031

        14.4.1. Infectious Diseases

        14.4.2. Oncology

        14.4.3. Ophthalmology

        14.4.4. Urology

        14.4.5. Diabetes

        14.4.6. CNS

        14.4.7. Others

    14.5. Market Value Forecast, by Route of Administration, 2017–2031

        14.5.1. Oral

        14.5.2. Injectable

        14.5.3. Inhalation

        14.5.4. Transdermal

        14.5.5. Ocular

        14.5.6. Nasal

        14.5.7. Topical

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. GCC Countries

        14.6.2. South Africa

        14.6.3. Rest of Middle East & Africa

    14.7. Market Attractiveness Analysis

        14.7.1. By Delivery System

        14.7.2. By Application

        14.7.3. By Route of Administration

        14.7.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

    15.2. Market Share Analysis, by Company (2022)

    15.3. Company Profiles

        15.3.1. Novartis AG

            15.3.1.1. Company Overview

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Financial Overview

            15.3.1.5. Strategic Overview

        15.3.2. Amgen Inc.

            15.3.2.1. Company Overview

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Financial Overview

            15.3.2.5. Strategic Overview

        15.3.3. Oxford Biomedica PLC

            15.3.3.1. Company Overview

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Financial Overview

            15.3.3.5. Strategic Overview

        15.3.4. Sibiono GeneTech Co., Ltd.

            15.3.4.1. Company Overview

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Financial Overview

            15.3.4.5. Strategic Overview

        15.3.5. Shanghai Sunway Biotech Co., Ltd.

            15.3.5.1. Company Overview

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Financial Overview

            15.3.5.5. Strategic Overview

        15.3.6. Pfizer, Inc.

            15.3.6.1. Company Overview

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Financial Overview

            15.3.6.5. Strategic Overview

        15.3.7. Bayer AG

            15.3.7.1. Company Overview

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Financial Overview

            15.3.7.5. Strategic Overview

        15.3.8. Johnson & Johnson Services, Inc.

            15.3.8.1. Company Overview

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Financial Overview

            15.3.8.5. Strategic Overview

        15.3.9. Human Stem Cells Institute

            15.3.9.1. Company Overview

            15.3.9.2. Product Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Financial Overview

            15.3.9.5. Strategic Overview

List of Tables

Table 01: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031

Table 02: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Gene Delivery System Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031

Table 07: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 08: North America Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 09: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031

Table 11: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 12: Europe Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 13: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031

Table 15: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 16: Asia Pacific Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 17: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031

Table 19: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 20: Latin America Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 21: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Delivery System, 2017–2031

Table 23: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

List of Figures

Figure 01: Global Gene Delivery System Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

Figure 02: Global Gene Delivery System Market Revenue (US$ Mn), by Delivery System, 2022

Figure 03: Global Gene Delivery System Market Value Share, by Delivery System, 2022

Figure 04: Global Gene Delivery System Market Revenue (US$ Mn), by Application, 2022

Figure 05: Global Gene Delivery System Market Value Share, by Application, 2022

Figure 06: Global Gene Delivery System Market Revenue (US$ Mn), by Route of Administration, 2022

Figure 07: Global Gene Delivery System Market Value Share, by Route of Administration, 2022

Figure 08: Global Gene Delivery System Market Value Share, by Region, 2022

Figure 09: Global Gene Delivery System Market Value (US$ Mn) Forecast, 2023–2031

Figure 10: Global Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031

Figure 11: Global Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031

Figure 12: Global Gene Delivery System Market Value Share Analysis, by Application, 2022–2031

Figure 13: Global Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031

Figure 14: Global Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 15: Global Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 16: Global Gene Delivery System Market Value Share Analysis, by Region, 2022–2031

Figure 17: Global Gene Delivery System Market Attractiveness Analysis, by Region, 2023–2031

Figure 18: North America Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 19: North America Gene Delivery System Market Attractiveness Analysis, by Country, 2023–2031

Figure 20: North America Gene Delivery System Market Value Share Analysis, by Country, 2022–2031

Figure 21: North America Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031

Figure 22: North America Gene Delivery System Market Value Share Analysis, by Application, 2022–2031

Figure 23: North America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 24: North America Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031

Figure 25: North America Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031

Figure 26: North America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 27: Europe Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 28: Europe Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Europe Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 30: Europe Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031

Figure 31: Europe Gene Delivery System Market Value Share Analysis, by Application, 2022–2031

Figure 32: Europe Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 33: Europe Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031

Figure 34: Europe Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031

Figure 35: Europe Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 36: Asia Pacific Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 37: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 38: Asia Pacific Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 39: Asia Pacific Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031

Figure 40: Asia Pacific Gene Delivery System Market Value Share Analysis, by Application, 2022–2031

Figure 41: Asia Pacific Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 42: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031

Figure 43: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031

Figure 44: Asia Pacific Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 45: Latin America Gene Delivery System Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 46: Latin America Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 47: Latin America Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 48: Latin America Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031

Figure 49: Latin America Gene Delivery System Market Value Share Analysis, by Application, 2022–2031

Figure 50: Latin America Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 51: Latin America Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031

Figure 52: Latin America Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031

Figure 53: Latin America Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031

Figure 54: Middle East & Africa Gene Delivery System Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 55: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 56: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Country/Sub-region, 2022–2031

Figure 57: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Delivery System, 2022–2031

Figure 58: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Application, 2022–2031

Figure 59: Middle East & Africa Gene Delivery System Market Value Share Analysis, by Route of Administration, 2022–2031

Figure 60: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Delivery System, 2023–2031

Figure 61: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Application, 2023–2031

Figure 62: Middle East & Africa Gene Delivery System Market Attractiveness Analysis, by Route of Administration, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved